Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Journey MedicalDERM +1.17%63 Equity-to-Asset is 0.34 as of Mar. 2026, which is 42% above its 10-year median of 0.24. GuruFocus rates DERM with a GF Score™ of 63/100 and a GF Value™ of $4.28 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Journey Medical ranks worse than 80.54% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Journey Medical's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $30.83 Mil. Journey Medical's Total Assets for the quarter that ended in Mar. 2026 was $91.53 Mil.
Therefore, Journey Medical's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.34.
The historical rank and industry rank for Journey Medical's Equity-to-Asset or its related term are showing as below:
DERM'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.13 Med: 0.24 Max: 0.43
Current: 0.34
During the past 7 years, the highest Equity to Asset Ratio of Journey Medical was 0.43. The lowest was -0.13. And the median was 0.24.
DERM's Equity-to-Asset is ranked worse than 80.54% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs DERM: 0.34
Journey Medical (NAS:DERM) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Journey Medical Equity-to-Asset Related Terms
Journey Medical Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Journey Medical's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DERM vs LFCR, ADCT, ANIK: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Journey Medical Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Journey Medical's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Journey Medical's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Journey Medical's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Journey Medical (DERM) has a Equity-to-Asset of 0.34 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Journey Medical and its competitors. This is 42% above median its historical median of 0.24. According to the industry distribution chart, Journey Medical ranks #811 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 80.5%.
Is Journey Medical's Equity-to-Asset too high?
Journey Medical's current Equity-to-Asset of 0.34 is 42% above median its 10-year median of 0.24. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Journey Medical's value of 0.34 is 44.3% below this industry median. Based on the distribution chart, Journey Medical ranks #811 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Journey Medical has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Journey Medical's Equity-to-Asset compare to LFCR and ADCT?
According to the Drug Manufacturers industry distribution chart, Journey Medical ranks #811 out of 1007 companies for Equity-to-Asset. This places Journey Medical in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Journey Medical's value of 0.34 is 44.3% below this benchmark. While the company's 10-year median is 0.24 vs. the industry median of 0.61, Journey Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Journey Medical's current Equity-to-Asset of 0.34 is 44.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Journey Medical and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Journey Medical's current Equity-to-Asset is 0.34, which is 42% above median its own 10-year median of 0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Journey Medical stock overvalued right now?
Based on GuruFocus' analysis, Journey Medical (DERM) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.28, compared to a current price of $6.48 — trading 51.3% above its estimated fair value. The current Equity-to-Asset is 0.34, which is 42% above median its 10-year median of 0.24 and 44.3% below the Drug Manufacturers industry median of 0.61. Journey Medical's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Journey Medical (DERM), the current Equity-to-Asset is 0.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Journey Medical (DERM) Overvalued in 2026?
Based on GuruFocus' analysis, Journey Medical stock appears to be overvalued.
The current stock price of $6.48 is trading 51.3% above its estimated GF Value™ of $4.28.
GuruFocus considers Journey Medical to be Significantly Overvalued.
Key valuation signals for DERM:
Equity-to-Asset: 0.34 (42% above median its 10-year median of 0.24)
GF Value™: $4.28 vs. price of $6.48 (51.3% above fair value)
Industry Position: 44.3% below the Drug Manufacturers median (#811 of 1007)
No single metric tells the full story. See the DERM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
63GF Score
Get the complete analysis for DERM
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DERM has been successfully added to your 
